Respicardia Revenue and Competitors

Claim your profile

Location

$160.2M

Total Funding

Estimated Revenue & Valuation

  • Respicardia's estimated annual revenue is currently $24.1M per year.(i)
  • Respicardia received $58.5M in venture funding in December 2017.
  • Respicardia's estimated revenue per employee is $251,000
  • Respicardia's total funding is $160.2M.

Employee Data

  • Respicardia has 96 Employees.(i)
  • Respicardia grew their employee count by 10% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$43.1M21910%$38.2MN/A

Founded in 2006 and headquartered near Minneapolis, Minnesota, Respicardia® is dedicated to improving the lives of heart failure patients by developing implantable therapies designed to improve respiratory rhythm management and cardiovascular health. The first product, the remed® System, is an implantable stimulation device that is designed to restore a more normal breathing pattern during sleep for patients with central sleep apnea. Respicardia® is committed to improving cardiovascular healthone breath at a time.

keywords:Biotechnology,Healthcare,Medical Devices,Pharmaceuticals

$160.2M

Total Funding

96

Number of Employees

$24.1M

Revenue (est)

10%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Respicardia News

2022-04-20 - Sleep Apnea Implants Market Competitive Insight, Demand ...

Medtronic, Respicardia Inc., Inspire Medical Systems, Siesta Medical Inc., LivaNova PLC, and LinguaFlex. Key Benefits For Stakeholders.

2022-04-17 - Sleep Apnea Implants Market Key Players- Inspire Medical Systems ...

Sleep Apnea Implants Market Key Players- Inspire Medical Systems, Respicardia, Inc., Medtronic Plc, LinguaFlex LLC, Siesta Medical, Inc.

2019-09-03 - New med-tech investment firm Vensana Capital launches $225 million fund

At Versant, he invested in a number of Minnesota companies like Metavention, Respicardia and Monteris Medical. Vensana, however, isn't ...

2019-09-03 - Study: Respicardia's sleep apnea tech effective over 3 years

A new study of Respicardia's Remede central sleep apnea (CSA) implant showed long-term safety and sustained improvement in sleep metrics ...

2019-01-14 - Integer Supports Respicardia's Commercialization in the ...

“We're honored to continue supporting Respicardia in bringing their therapy to market,” said Tony Gonzalez, president of Integer's Cardiac ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$17.3M96-4%N/A
#2
$20.4M97-19%N/A
#3
$14.8M10220%N/A
#4
$1.7M10216%N/A
#5
$25.5M10216%N/A

Respicardia Funding

DateAmountRoundLead InvestorsReference
2014-07-14$2.0MUndisclosedArticle
2014-10-30$20.0MUndisclosedSorin GroupArticle
2017-12-19$58.5MUndisclosedZOLL Medical CorporationArticle